ADAP
Adaptimmune Therapeutics PLCCompany Information
- Company Name
- Adaptimmune Therapeutics PLC
- CIK
- CIK0001621227
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ADAP: None, ADAPY: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- ADAP
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2025-09-02
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 42,529,570
Institutional Sentiment
- As of
- 2025-09-30
- Institutional shares owned
- 40,567,195
- Shares outstanding
- 264,087,145
- Ownership
- 15.36%
Earnings Market Reaction
- Filing date
- 2025-08-13
- Price on filing date
- —
- 1-month reaction
- -47.57%
- 3-month reaction
- -35.81%
Balance Sheet
Values in millions ($)| Line item | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 26 | 41 | 91 | 117 | 212 | 141 | 144 | 90 | 77 | 120 | 108 | 79 | ||||||
| Available For Sale Securities Debt Securities Current | 0 | 19 | 60 | 69 | 3 | 3 | 3 | 72 | 128 | 46 | 97 | 121 | ||||||
| Accounts Receivable Net Current | 9 | 4 | 1 | 13 | 2 | 8 | 1 | 1 | 3 | 2 | 7 | 2 | ||||||
| Inventory Net | 11 | 12 | 7 | 2 | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 31 | 27 | 28 | 44 | 37 | 35 | 60 | 57 | 54 | 46 | 43 | 63 | ||||||
| Assets Current | 78 | 103 | 188 | 244 | 254 | 187 | 208 | 219 | 262 | 214 | 255 | 264 | ||||||
| Restricted Cash And Cash Equivalents Noncurrent | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | ||||||
| Other Assets Noncurrent | 0 | 0 | 1 | 1 | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 19 | 19 | 20 | 20 | 18 | 19 | 21 | 21 | 22 | 18 | 18 | 18 | ||||||
| Property Plant And Equipment Net | 28 | 30 | 31 | 45 | 46 | 48 | 51 | 53 | 55 | 54 | 54 | 48 | ||||||
| Intangible Assets Net Excluding Goodwill | 4 | 4 | 4 | 4 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Assets | 131 | 158 | 246 | 317 | 322 | 258 | 283 | 297 | 343 | 288 | 329 | 332 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 9 | 6 | 9 | 9 | 8 | 7 | 8 | 14 | 15 | 5 | 5 | 7 | ||||||
| Operating Lease Liability Current | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 3 | 3 | 2 | ||||||
| Accrued Liabilities Current | 25 | 25 | 33 | 32 | 31 | 23 | 30 | 27 | 25 | 33 | 31 | 36 | ||||||
| Restructuring Reserve | 2 | 3 | 6 | - | - | - | - | - | - | 0 | 2 | - | ||||||
| Contract With Customer Liability Current | 11 | 12 | 12 | 19 | 38 | 32 | 29 | 29 | 31 | 22 | 24 | 21 | ||||||
| Liabilities Current | 52 | 51 | 65 | 63 | 82 | 66 | 73 | 75 | 76 | 64 | 65 | 66 | ||||||
| Operating Lease Liability Noncurrent | 18 | 19 | 19 | 20 | 17 | 18 | 20 | 21 | 22 | 20 | 20 | 20 | ||||||
| Deferred Revenue Noncurrent | - | 96 | 96 | 99 | 100 | - | 149 | - | - | - | - | - | ||||||
| Contract With Customer Liability Noncurrent | 101 | - | - | - | - | 147 | 149 | 111 | 117 | 119 | 161 | 132 | ||||||
| Long Term Debt Noncurrent | 26 | 25 | 50 | 50 | 25 | - | - | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | 4 | 4 | 4 | 5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities | 202 | 196 | 234 | 237 | 225 | 234 | 243 | 209 | 216 | 204 | 247 | 219 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | ||||||
| Additional Paid In Capital | 1,109 | 1,106 | 1,106 | 1,103 | 1,100 | 1,097 | 1,065 | 1,061 | 1,058 | 993 | 991 | 985 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -11 | -4 | -2 | -5 | -3 | -3 | -4 | 0 | -3 | -2 | -1 | 7 | ||||||
| Retained Earnings Accumulated Deficit | -1,172 | -1,142 | -1,094 | -1,020 | -1,002 | -1,072 | -1,023 | -975 | -930 | -908 | -909 | -880 | ||||||
| Stockholders Equity | -71 | -37 | 12 | 80 | 96 | 24 | 40 | 88 | 127 | 84 | 82 | 113 | ||||||
| Liabilities And Stockholders Equity | 131 | 158 | 246 | 317 | 322 | 258 | 283 | 297 | 343 | 288 | 329 | 332 | ||||||
| Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss Current | 0 | 19 | 60 | 69 | 3 | 3 | 3 | - | - | - | 98 | - | ||||||
| Debt Securities Available For Sale Allowance For Credit Loss Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Allowance For Doubtful Accounts Receivable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset Accumulated Amortization | - | 19 | 18 | - | - | 14 | 13 | - | - | 10 | 9 | - | ||||||
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 75 | 70 | 52 | 56 | 51 | 48 | 46 | 43 | 41 | 39 | 39 | 35 | ||||||
| Amortization Of Intangible Assets | - | - | - | - | - | - | - | - | - | - | - | 4 | ||||||
| Finite Lived Intangible Assets Accumulated Amortization | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 351 | 340 | 340 | 340 | 340 | 284 | 284 | 284 | 284 | 214 | 214 | 214 | ||||||
| Common Stock Shares Issued | 265 | 258 | 256 | 256 | 256 | 255 | 227 | 227 | 225 | 166 | 165 | 164 | ||||||
| Shares Outstanding | 265 | 258 | 256 | 256 | 256 | 255 | 227 | 227 | 225 | 166 | 165 | 164 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAdaptimmune Therapeutics PLC (ADAP) — SEC Financial Statements & Analysis
Adaptimmune Therapeutics PLC (ADAP) is a biological products, (no diagnostic substances) company, incorporated in X0. Adaptimmune Therapeutics PLC trades on None, OTC as: ADAP, ADAPY. Adaptimmune Therapeutics PLC (ADAP)'s most recent SEC filing is a Form 10-Q for the period ended 2025-06-30, filed with the SEC on 2025-08-13. Based on that filing, On profitability, Adaptimmune Therapeutics PLC posts an operating margin of -252.32%, a net margin of -260.82%, a Return on Equity (ROE) of -1341.10%, a Return on Assets (ROA) of -75.06%, and a Return on Invested Capital (ROIC) of -862.80%. Per share, it reports EPS of $-0.64, diluted EPS of $-0.64, free cash flow per share of $-0.73, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -53.99% year-over-year, net income growth of 134.15% year-over-year, and EPS growth of 126.61% year-over-year. On the balance sheet, it maintains a current ratio of 1.52x, a quick ratio of 0.69x, working capital of $26.60M, a debt-to-equity ratio of -2.84x, a debt ratio of 1.54, an interest coverage ratio of -28.99x, free cash flow of $-191.67M (TTM), and net debt of $-2.10M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-0.64
- ROE TTM
- -1341.10%
- ROA TTM
- -75.06%
- Debt To Equity
- -2.84x
- Free Cash Flow TTM
- $-191.67M
- Net Revenue TTM Growth 1Y
- -53.99%
Data as of 2025-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Adaptimmune Therapeutics PLC in?
Adaptimmune Therapeutics PLC (ADAP) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does ADAP trade on?
Adaptimmune Therapeutics PLC (ADAP) trades on the None, OTC.
Where is Adaptimmune Therapeutics PLC incorporated?
Adaptimmune Therapeutics PLC is incorporated in United Kingdom.
When was Adaptimmune Therapeutics PLC (ADAP)'s most recent SEC filing?
Adaptimmune Therapeutics PLC (ADAP)'s most recent SEC filing is a Form 10-Q for the period ended 2025-06-30, filed with the SEC on 2025-08-13.
What is ADAP's EPS (earnings per share)?
Adaptimmune Therapeutics PLC (ADAP)'s trailing twelve month EPS is $-0.64 as of 2025-06-30.
What is ADAP's ROE (return on equity)?
Adaptimmune Therapeutics PLC (ADAP)'s trailing twelve month Return on Equity (ROE) is -1341.10% as of 2025-06-30.
What is ADAP's ROA (return on assets)?
Adaptimmune Therapeutics PLC (ADAP)'s trailing twelve month Return on Assets (ROA) is -75.06% as of 2025-06-30.
What is ADAP's ROIC (return on invested capital)?
Adaptimmune Therapeutics PLC (ADAP)'s trailing twelve month Return on Invested Capital (ROIC) is -862.80% as of 2024-09-30.